Clinical trial
A Double-blind, Placebo-controlled, Exploratory Randomised Clinical Trial to Assess the Safety and Efficacy of IFB-088 Plus Riluzole 100 mg vs Placebo Plus Riluzole 100 mg in Patients With Bulbar-onset Amyotrophic Lateral Sclerosis.
NCT05508074 is registered in ClinicalTrials.gov with InFlectis BioScience as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Placebo-controlled, Exploratory Randomised Clinical Trial to Assess the Safety and Efficacy of IFB-088 Plus Riluzole 100 mg vs Placebo Plus Riluzole 100 mg in Patients With Bulbar-onset Amyotrophic Lateral Sclerosis.
- Lead sponsor
- InFlectis BioScience
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 2, 2022
- Completion date
- January 20, 2025
- Enrollment
- 51 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.